top of page

Investor Relations

Press Releases


Jan 30, 2024

Estrella Immunopharma Announces $1 Million Share Repurchase Authorization


Jan 24, 2024

Estrella Immunopharma Announces Publication in Blood Demonstrating ARTEMIS T Cell’s Potential in Addressing Acute Myeloid Leukemia (AML)


Sep 29, 2023

TradeUP Acquisition Corp. and Estrella Biopharma, Inc. Announce Completion of Business Combination


Mar 8, 2023

Estrella Biopharma Announces FDA Clearance of IND Application for Phase I/II Clinical Trial (Starlight-1) of EB103, a CD19-Targeted ARTEMIS® T Cell Therapy, to Patients with B-Cell Lymphomas


Nov 14, 2022

Imugene’s onCARlytics combination with Estrella’s CD19-Redirected ARTEMIS® T Cells presented at SITC Annual Meeting


Oct 3, 2022

Estrella Biopharma, Inc., a biopharmaceutical company to Become a Publicly Traded Company Via Merger with TradeUP Acquisition Corp.

Anchor 1
bottom of page